Table 3 |
|||
|
Haemoglobin concentration, anaemia, and parasitaemia among participants in an antimalarial in vivo efficacy study, Faladje, Mali. |
|||
|
Characteristics |
AS+AQ |
AS+SP |
AQ+SP |
|
|
|||
|
Day 0 |
|||
|
N |
133 |
132 |
132 |
|
Mean Haemoglobin ± S.D (g/dl) |
9.83 ± 1.8 |
9.71 ± 1.59 |
9.98 ± 1.59 |
|
Anaemia (< 11 g/dl), n (%) |
93 (69.9) |
102 (77.3) |
97 (73.5) |
|
Day 14 |
|||
|
N |
131 |
130 |
130 |
|
§Mean Haemoglobin ± S.D (g/dl) |
10.17 ± 1.5 |
9.89 ± 1.40 |
10.43 ± 1.49 |
|
*Anaemia (< 11 g/dl), n (%) |
87 (65.9) |
100 (77.5) |
81 (61.4) |
|
Day 28 |
|||
|
N |
105 |
127 |
130 |
|
§SMean Haemoglobin ± S.D (g/dl) |
10.78 ± 1.49 |
10.5 ± 1.40 |
11.05 ± 1.52 |
|
**Anaemia (< 11 g/dl), n (%) |
57(54.3) |
76 (59.8) |
60 (46.2) |
|
|
|||
|
Parasitaemia, n (%) |
|||
|
€Day2 |
14(10.5) |
14(10.7) |
67(50.7) |
|
€Day3 |
2(1.5) |
1(0.8) |
8 (6.0) |
|
Day14 |
5(3.8) |
2(1.6) |
2(1.5) |
|
€Day28 |
31(29.5) |
9(7.1) |
3(2.3) |
|
|
|||
|
AS+AQ, artesunate + amodiaquine; AS+SP, artesunate + sulphadoxine-pyrimethamine; AQ+SP, amodiaquine + sulphadoxine-pyrimethamine *X 2 test: p = 0.014 overall (2 × 3); p = 0.030, AS+SP vs. AS+AQ; p = 0.0046, AS+SP vs. AQ+SP; p = 0.48, AS+AQ vs. AQ+SP. **X 2 test: p = 0.08 overall (2 × 3); p = 0.027, AQ+SP vs. AS+SP; p = 0.21, AQ+SP vs. AS+AQ; p = 0.39, AS+AQ vs. AS+SP §Paired t-test comparison day 0 vs. day 14: overall, p < 0.01; AQ+SP, p = 0.001; AS+AQ, p = 0.011; AS+SP, p = 0.033. §SPaired t-test comparison day 0 vs. day 28: overall, p < 0.001; AQ+SP, p < 0.001; AS+AQ, p < 0.001; AS+SP, p < 0.001 €X 2 test: overall (2 × 3); Time points showing difference among the three groups: Day 2, p < 0.001; Day3, p = 0.017; Day 28, p < 0.001. |
|||
|
Kayentao et al. Malaria Journal 2009 8:5 doi:10.1186/1475-2875-8-5 |
|||
